Neuroimaging is widely used in Parkinson's disease patients to improve diagnosis, provide insights into the natural history of disease, and facilitate the development of new treatments. Different MRI sequences and contrasts have been employed to study structure and function, whilst PET have been used to image receptors, transporters, enzymes and metabolism. In this study we evaluate relationships between pathological and functional markers of neurodegeneration using a range of advanced MRI and PET methods, in the same subjects, cross sectionally and over time. To the best of our knowledge this combination of markers has yet to be reported.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: